A Canadian partnership with international ties to advance the field of psychedelic medicine globally with standardized extracts A leader in naturally-derived psilocybin for extraction, production of advanced formulations and clinical research TORONTO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) and Pure Extracts Technologies Corp. (CSE: PULL) (OTC…


Previous articlePharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor
Next articleMINDCURE Announces Commencement of Trading on the OTCQX Best Market